The Mayo Clinic Cancer Center (MCCC) is a matrix center within the Mayo Clinic / Mayo Medical School. The Center is made up of 351 members from 87 departments and divisions based at 3 geographical sites (Rochester, MN - MGR; Jacksonville, FL - MCF; and Phoenix/ Scottsdale, AZ - MCA). Our mission is to promote and facilitate research on the incidence, etiology, and molecular basis of cancer, and then through education and direct application of the results of such research, translate the discoveries into improved methods for cancer prevention, detection, diagnosis, prognosis, and therapy. MCCC, like Mayo Clinic in general, serves not only patients in the immediate geographical areas of MGR, MCF, and MCA, but also patients from throughout the USA and the rest of the world. MCCC has 10 research programs: Cell Biology; Developmental Therapeutics; Cancer Immunology & Immunotherapy; Gene & Virus Therapy; Women's Cancer; Gastrointestinal Cancer; Hematologic Malignancies; Neuro-oncology; Genetic Epidemiology & Risk Assessment; and Cancer Prevention & Control. Research is facilitated by: 1) 13 shared resources: Survey Research, Pharmacy, Biostatistics, Bioinformatics, Biospecimens Accessioning & Processing, Pathology Research Core, Transgenic & Knockout Core, Proteomics, Microscopy & Cell Analysis, Pharmacology, Gene & Virus Therapy, Cytogenetics, and Gene Analysis; and 2) clinical support management activities including Clinical Trials Office, PRMS, and Data & Safety Monitoring. Since the last renewal, MCCC has grown with an increase in overall peer-reviewed funding from $105.9M to $123.6M and an increase in NCI funding from $75.7M to $92.7M. Of particular note is a new Ovarian SPORE and a new training grant. Furthermore, there has been successful competitive renewal of 4 other SPOREs (Lymphoma, Brain, Breast, Pancreas), as well as several multi-disciplinary and training grants. Research productivity and excellence is demonstrated by high-impact clinical and scientific publications - several of which have led to changes in cancer care. As the MCCC moves forward, a major cross-programmatic effort will be to build on research started during the past grant period in the cancer genome with the development of new genome-guided therapy approaches.

Public Health Relevance

The Mayo Clinic Cancer Center Support Grant provides the infrastructure support to facilitate basic, clinical, and population sciences research relevant to cancer research conducted within Mayo Clinic. The Center's goal is to translate the discoveries in the laboratory into improved methods for cancer prevention, detection, diagnosis, prognosis, and therapy. The ultimate goal is to relieve the burdens of illness in patients with canner.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-44
Application #
9437706
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1997-04-25
Project End
2019-02-28
Budget Start
2018-03-01
Budget End
2019-02-28
Support Year
44
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430
Dasari, Surendra; Newsom, Sean A; Ehrlicher, Sarah E et al. (2018) Remodeling of skeletal muscle mitochondrial proteome with high-fat diet involves greater changes to ?-oxidation than electron transfer proteins in mice. Am J Physiol Endocrinol Metab 315:E425-E434
Nowsheen, Somaira; Aziz, Khaled; Aziz, Asef et al. (2018) L3MBTL2 orchestrates ubiquitin signalling by dictating the sequential recruitment of RNF8 and RNF168 after DNA damage. Nat Cell Biol 20:455-464
Razidlo, Gina L; Burton, Kevin M; McNiven, Mark A (2018) Interleukin-6 promotes pancreatic cancer cell migration by rapidly activating the small GTPase CDC42. J Biol Chem 293:11143-11153
Wu, Dongyan; Yang, Haitao; Winham, Stacey J et al. (2018) Mediation analysis of alcohol consumption, DNA methylation, and epithelial ovarian cancer. J Hum Genet 63:339-348
Leon-Ferre, Roberto A; Polley, Mei-Yin; Liu, Heshan et al. (2018) Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. Breast Cancer Res Treat 167:89-99
Jahanseir, Khadijeh; Xing, Deyin; Greipp, Patricia T et al. (2018) PDGFB Rearrangements in Dermatofibrosarcoma Protuberans of the Vulva: A Study of 11 Cases Including Myxoid and Fibrosarcomatous Variants. Int J Gynecol Pathol 37:537-546
Painter, Jodie N; O'Mara, Tracy A; Morris, Andrew P et al. (2018) Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. Cancer Med 7:1978-1987
Yu, Jia; Qin, Bo; Moyer, Ann M et al. (2018) DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Invest 128:2376-2388
Sugihara, Takaaki; Werneburg, Nathan W; Hernandez, Matthew C et al. (2018) YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity. Mol Cancer Res 16:1556-1567

Showing the most recent 10 out of 1129 publications